06.07.17
Ganeden has introduced an immune health ingredient, Staimune, using its patented probiotic strain. The new ingredient utilizes the cells of the probiotic GanedenBC30 to support immune health, at cost effective inclusion levels, the company said.
Officially identified as “Inactivated Bacillus coagulans GBI-30, 6086,” Staimune’s ease of formulation opens up new opportunities in functional foods and beverages—most importantly in shelf-stable beverages and high-water-activity products. Staimune is FDA GRAS, non-GMO, organic compliant and kosher, making it accessible for use in a vast amount of applications.
Multiple peer-reviewed and published studies show the immune health benefits of GanedenBC30 cells, with additional in vitro and human clinical studies on Staimune currently underway.
“After seeing the impressive immune supporting benefits of GanedenBC30, we decided to dive further into the mechanism of action,” said Michael Bush, president and CEO of Ganeden. “We discovered and ultimately patented this novel ingredient which provides the opportunity to share the immune benefits of the probiotic in product formats that do not support the use of the live organism.”
Staimune provides the option for manufacturers that want to focus specifically on immune health, and for those with processes that cause formulation challenges for live probiotics. With an inclusion rate of just 50 mg, Staimune does not alter the flavor or texture profiles of finished goods, allowing for easy application into a large number of product categories, according to Ganeden.
Staimune will be available for formulation starting in the summer of 2017.
Officially identified as “Inactivated Bacillus coagulans GBI-30, 6086,” Staimune’s ease of formulation opens up new opportunities in functional foods and beverages—most importantly in shelf-stable beverages and high-water-activity products. Staimune is FDA GRAS, non-GMO, organic compliant and kosher, making it accessible for use in a vast amount of applications.
Multiple peer-reviewed and published studies show the immune health benefits of GanedenBC30 cells, with additional in vitro and human clinical studies on Staimune currently underway.
“After seeing the impressive immune supporting benefits of GanedenBC30, we decided to dive further into the mechanism of action,” said Michael Bush, president and CEO of Ganeden. “We discovered and ultimately patented this novel ingredient which provides the opportunity to share the immune benefits of the probiotic in product formats that do not support the use of the live organism.”
Staimune provides the option for manufacturers that want to focus specifically on immune health, and for those with processes that cause formulation challenges for live probiotics. With an inclusion rate of just 50 mg, Staimune does not alter the flavor or texture profiles of finished goods, allowing for easy application into a large number of product categories, according to Ganeden.
Staimune will be available for formulation starting in the summer of 2017.
